What Is IgG4-Related Disease? An Autoimmune Condition

IgG4-related disease (IgG4-RD) is a chronic condition in which the immune system drives inflammation and scarring across one or more organs, forming mass-like swellings that can look alarmingly like cancer on a scan. It was only recognized as a unified disease in the early 2000s, after researchers realized that a long list of mysterious organ-specific conditions, each with its own name, shared the same underlying pathology.¹ Despite the “autoimmune” label it often receives, IgG4-RD sits in an unusual immunological gray zone, and the details of how and why it develops are still being worked out.

A Disease That Was Hiding in Plain Sight

For decades, doctors in different specialties were independently treating what turned out to be the same disease. Gastroenterologists managed a form of pancreatitis that shrank with steroids. Ophthalmologists removed swollen tissue from eye sockets. Nephrologists puzzled over a peculiar type of kidney inflammation. Each organ-specific version had its own name, and nobody connected them. The unifying insight came when pathologists noticed a shared tissue signature: dense clusters of immune cells, a distinctive swirling pattern of scar tissue, and elevated levels of a particular antibody subclass called IgG4. Recognizing that pattern across organs turned dozens of seemingly unrelated diagnoses into one systemic disease.¹

Which Organs Does It Affect

IgG4-RD can show up in virtually any organ, though some sites are far more common than others. The pancreas is the most recognized target: autoimmune pancreatitis is essentially IgG4-RD of the pancreas, and it was the condition that first led researchers toward the broader disease concept.² Beyond the pancreas, the salivary glands, tear glands, bile ducts, kidneys, retroperitoneum (the space behind the abdominal organs), thyroid, lungs, lymph nodes, and prostate can all be involved, sometimes simultaneously and sometimes one after another over months or years.³

A hallmark of the disease is that it tends to form mass-like lesions, which means a patient’s first encounter with IgG4-RD is often a scan showing what looks like a tumor. Because the masses can appear in the pancreas, bile ducts, or retroperitoneum, cancer is frequently the initial suspicion.² One case series highlighted a patient presenting with multiple space-occupying lesions and fluid collections that strongly suggested metastatic cancer; biopsy ultimately revealed IgG4-RD instead.⁴

The retroperitoneum deserves special mention because IgG4-RD is one of the leading causes of retroperitoneal fibrosis, a condition where scar tissue encases the aorta, ureters, or other structures. A significant fraction of inflammatory abdominal aortic aneurysms and periaortitis cases turn out to be driven by IgG4-RD.⁵ In the kidneys, IgG4-RD typically presents as tubulointerstitial nephritis, which can quietly damage kidney function before anyone connects it to the broader disease.⁶

Who Gets It

IgG4-RD is uncommon, and for years the conventional wisdom held that it overwhelmingly affected middle-aged and older men, based largely on Japanese studies of autoimmune pancreatitis. More recent data from the United States paint a somewhat different picture. A large claims-based study found a mean age at diagnosis of about 57, but with roughly 58 percent of patients being female, suggesting the old male-predominant stereotype may partly reflect which organ manifestations were studied first rather than who actually gets the disease overall.⁷

What triggers the disease in a given person is still uncertain, but one emerging thread is environmental exposure. A review of environmental risk factors found that a history of blue-collar work increases the risk of developing IgG4-RD, with mineral dusts and asbestos showing the strongest associations among industrial compounds.⁸ The going theory is that genetic susceptibility combined with chronic environmental irritation may set off the abnormal immune activation that sustains the disease.

What Is Happening Inside the Tissue

The “IgG4” in the disease’s name refers to a subclass of antibody, immunoglobulin G4. Your immune system makes four subclasses of IgG, and IgG4 is the least abundant under normal circumstances. It also behaves oddly compared to the other three. IgG4 antibodies can split in half and recombine with halves from other IgG4 molecules, a process called Fab-arm exchange, which produces hybrid antibodies that bind two different targets.⁹ This molecular shuffling is thought to make IgG4 functionally anti-inflammatory under normal conditions, which is one reason the disease is so puzzling: why would an increase in an anti-inflammatory antibody be associated with destructive inflammation?

The answer, increasingly, is that IgG4 itself may be more of a bystander than a driver. Research over the past decade has shifted attention to specific immune cells infiltrating affected tissues. One critical player is a type of killer T cell. These CD4-positive cytotoxic T cells are clonally expanded in IgG4-RD tissue sites, meaning the same T cell has multiplied enormously in the affected organ. These cells produce molecules associated with both tissue damage and scar formation.¹⁰ When patients are treated with rituximab, a drug that depletes B cells (the cells that make antibodies), these disease-driving T cells also decline, and symptoms improve, which suggests B cells and T cells are cooperating in a feedback loop.¹⁰

The fibrosis, or scarring, that gives IgG4-RD its destructive character appears to be driven in part by a type of immune cell called M2 macrophages. Studies have found significantly higher numbers of these macrophages in IgG4-RD tissue compared to other inflammatory conditions, and their abundance correlates directly with the severity of organ scarring.¹¹ These macrophages promote fibrosis through specific signaling pathways, and in mouse models, activating the same pathway produces organ scarring that mirrors what is seen in human patients.¹²

Why It Takes So Long to Diagnose

Getting an IgG4-RD diagnosis is often a prolonged, frustrating process. A cross-sectional survey of patients in the United States found that the average time from symptom onset to diagnosis was about 11.5 months, and patients saw an average of 3.3 different providers before arriving at the correct answer. Perhaps most strikingly, a different diagnosis was initially suspected in over 90 percent of patients, with conditions like pancreatitis, chronic fatigue syndrome, and vasculitis among the most common wrong turns.¹³

Part of the difficulty is that IgG4-RD does not produce a single recognizable symptom. A patient with salivary gland swelling looks like Sjögren’s syndrome. A patient with a pancreatic mass looks like pancreatic cancer. A patient with kidney inflammation looks like any number of nephritis causes. The disease’s presentation depends entirely on which organ is involved, so it can masquerade as almost anything.

How Doctors Confirm the Diagnosis

Diagnosis rests on a combination of blood tests, imaging, and tissue biopsy. A serum IgG4 level is usually the first test ordered, and across pooled studies it performs reasonably well, with sensitivity around 85 to 87 percent and specificity around 83 to 93 percent depending on the cutoff used.¹⁴ That said, the blood test alone is not sufficient. IgG4 levels can be elevated in other conditions, and some people with confirmed IgG4-RD have normal serum levels. One meta-analysis described serum IgG4 as a “modestly effective marker,” noting that raising the threshold to improve specificity sacrifices a substantial amount of sensitivity.¹⁵

Tissue biopsy remains the gold standard. The three hallmark findings under the microscope are a dense infiltrate of immune cells (especially plasma cells), a swirling, cartwheel-like pattern of scar tissue called storiform fibrosis, and obliterative phlebitis, in which veins within the tissue are choked shut by inflammation.¹⁶ In addition to these architectural features, pathologists look for an elevated ratio of IgG4-positive to total IgG-positive plasma cells, typically above 40 percent, along with organ-specific minimum counts of IgG4-positive cells.¹⁷

In 2019, a formal classification framework was published jointly by the American College of Rheumatology and the European League Against Rheumatism. It uses a three-step process: first confirming involvement of at least one of 11 defined organs in a pattern consistent with IgG4-RD, then applying 32 exclusion criteria to rule out mimics, and finally scoring weighted inclusion criteria across clinical, blood-test, imaging, and biopsy findings. A score of 20 or higher classifies a case as IgG4-RD, and in validation studies this threshold achieved specificity above 98 percent with sensitivity in the range of 77 to 86 percent.¹⁸¹⁹

Imaging also plays an important role. PET/CT scans, which highlight areas of high metabolic activity, are useful for mapping the full extent of organ involvement, guiding biopsy to the most active site, and tracking whether treatment is working.²⁰ This is especially helpful because IgG4-RD often affects multiple organs simultaneously, and identifying all sites of disease early matters for treatment planning.

Treatment and the Relapse Problem

The first-line treatment for IgG4-RD is glucocorticoids, typically prednisone, and the response is often dramatic. In a multicenter study, over 80 percent of patients treated with steroids were classified as responders.²¹ Organ swelling decreases, IgG4 levels fall, and symptoms improve, sometimes within days. This rapid steroid response is actually considered a supportive diagnostic clue; if a patient with suspected IgG4-RD does not respond to steroids at all, the diagnosis warrants reconsideration.²²

The catch is that IgG4-RD relapses frequently once steroids are tapered, and long-term steroid use carries well-known side effects: weight gain, bone thinning, elevated blood sugar, and increased infection risk. This creates a difficult cycle where patients improve on high-dose steroids, relapse when the dose comes down, and are put back on steroids again.

Rituximab, a drug that depletes B cells, has become the leading steroid-sparing option. In a prospective trial, 97 percent of participants responded to rituximab, and about half achieved complete remission by six months.²³ However, rituximab’s effects are not permanent. B cells repopulate over time, and without maintenance dosing, relapse rates are high. One study found that patients who received rituximab every six months as maintenance therapy had a relapse rate of 29 percent at 18 months, compared to 100 percent relapse in those who did not receive maintenance infusions.²⁴ The implication is clear: for many patients, IgG4-RD requires ongoing immunosuppressive therapy, not a one-time course.

Emerging Treatments

The need for better long-term options has driven a pipeline of clinical trials. Several drugs targeting B cells through different mechanisms are under investigation. Inebilizumab and obexelimab target CD19, a protein found on a broader range of B cells than the CD20 protein that rituximab targets. Belimumab, which blocks a B-cell survival signal called BAFF, is also being studied. A separate line of investigation involves Bruton’s tyrosine kinase inhibitors, small-molecule drugs originally developed for blood cancers, with zanubrutinib and rilzabrutinib both in trials for IgG4-RD.²⁵ Whether any of these will eventually replace the steroid-then-rituximab sequence as the standard approach remains to be seen, but the growing treatment landscape reflects how seriously IgG4-RD is now taken as a disease worth targeting specifically.

The Link Between IgG4-RD and Cancer

One of the more unsettling findings in IgG4-RD research is an association with increased cancer risk. A nationwide South Korean cohort study found that patients with IgG4-RD had roughly four times the expected rate of cancer overall, with particularly elevated risks for pancreatic cancer, biliary tract cancer, and blood cancers such as non-Hodgkin lymphoma and myelodysplastic syndrome.²⁶ A Chinese prospective cohort found a somewhat lower but still significant elevation, roughly 2.8 times the expected cancer rate, with autoimmune pancreatitis as an independent risk factor for developing cancer among IgG4-RD patients.²⁷ A Japanese study with long-term follow-up similarly found about twice the expected malignancy rate overall, with the risk concentrated in the first year after IgG4-RD diagnosis.²⁸

The concentration of cancer risk in the first year raises an important question: is the immune dysfunction of IgG4-RD actually promoting cancer, or are some cancers being misdiagnosed as IgG4-RD early on and only recognized later? The honest answer is that both are probably happening. Some early cancers generate inflammatory responses that mimic IgG4-RD pathology, and some cases of IgG4-RD may genuinely create an immune environment that favors tumor development. Either way, the practical takeaway is the same: newly diagnosed IgG4-RD patients warrant close monitoring for malignancy, particularly in the pancreas and biliary system.

Why “Autoimmune” Is Complicated Here

IgG4-RD is routinely called autoimmune, and the label is not wrong exactly, but it is incomplete. In classic autoimmune diseases like lupus or rheumatoid arthritis, the immune system generates antibodies against specific self-proteins, and those antibodies directly cause tissue damage. In IgG4-RD, the role of IgG4 antibodies is less clear. The antibodies are abundant in affected tissues, and their serum levels often track with disease activity, but IgG4 antibodies are functionally unusual. Their ability to undergo Fab-arm exchange means they tend to become bispecific and lose the ability to activate the complement system and recruit inflammatory cells in the way other antibody subclasses do.⁹ Some researchers view the IgG4 response as the body’s attempt to dampen a pre-existing inflammatory process, not as the driver of that process.

The tissue damage appears to come primarily from the cellular side of the immune system, specifically the clonally expanded killer T cells and the pro-fibrotic macrophages described earlier, rather than from the antibodies themselves. This distinction matters for treatment: drugs that deplete B cells (which make antibodies) work, but likely because they interrupt the collaboration between B cells and the disease-driving T cells, not simply because they reduce antibody levels. It also explains why IgG4-RD does not fit neatly into the category of diseases most people think of when they hear “autoimmune.” It is fibroinflammatory, immune-mediated, and involves autoimmune features, but the mechanistic details do not match the textbook autoimmune playbook.

Living with the Diagnosis

For patients who respond well to initial treatment, the prognosis can be good. Organ damage from IgG4-RD is often at least partially reversible if caught before extensive fibrosis sets in, which is one of the strongest arguments for early diagnosis. Once dense scar tissue has replaced functional organ tissue, no drug can fully undo that damage, even if the underlying inflammation is brought under control. The pancreas, kidneys, and salivary glands are particularly vulnerable to irreversible fibrosis if treatment is delayed.

The relapsing nature of the disease means most patients need long-term relationships with specialists, often rheumatologists, who coordinate care across whatever organs are affected. Because IgG4-RD can involve so many body systems, a patient might simultaneously be managed by a gastroenterologist, nephrologist, and ophthalmologist, with the rheumatologist serving as the thread connecting them. The survey data showing an average of 3.3 provider consultations before diagnosis hints at how fragmented that care can be before anyone identifies the common thread.¹³ Awareness of IgG4-RD has grown rapidly since its formal recognition, but it remains underdiagnosed, particularly in settings where specialists are less accessible.

1
PubMed. IgG4-related disease
2
PubMed. Autoimmune pancreatitis and IgG4-related sclerosing disease
3
PubMed. IgG4-related sclerosing disease: autoimmune pancreatitis and extrapancreatic manifestations
4
PubMed Central. IgG4-Related Disease Mimicking Metastatic Malignancy: Polyserositis and Abdominal Lymphadenopathy
5
PubMed. Aortitis, periaortitis, and retroperitoneal fibrosis, as manifestations of IgG4-related systemic disease
6
PubMed Central. IgG4-Related Disease With Lung and Kidney Involvement: A Case Report
7
PubMed. Incidence, prevalence and mortality of IgG4-related disease in the USA: a claims-based analysis of commercially insured adults
8
PubMed. A Review on The Role of Environmental Exposures in IgG4-Related Diseases
9
PubMed. Mechanism of immunoglobulin G4 Fab-arm exchange
10
PubMed Central. Clonal expansion of CD4 + Cytotoxic T Lymphocytes in IgG4-related disease
11
PubMed. Preferential M2 macrophages contribute to fibrosis in IgG4-related dacryoadenitis and sialoadenitis, so-called Mikulicz’s disease
12
PubMed Central. Activated M2 Macrophages Contribute to the Pathogenesis of IgG4-Related Disease via Toll-like Receptor 7/Interleukin-33 Signaling
13
ACR Meeting Abstracts. Diagnostic Journey, Clinical Burden, And Quality Of Life Of Patients With IGg4-Related Disease: Results Of A Cross-Sectional Survey Of Patients And Physicians In The United States
14
PubMed Central. Diagnostic performance of serum IgG4 level for IgG4-related disease: a meta-analysis
15
PubMed Central. Diagnostic Value of Serum IgG4 for IgG4-Related Disease: A PRISMA-compliant Systematic Review and Meta-analysis
16
PubMed. Consensus statement on the pathology of IgG4-related disease
17
PubMed Central. IgG4-Related Disease: Current and Future Insights into Pathological Diagnosis
18
PubMed. The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related Disease
19
PubMed. The external validation of the 2019 ACR/EULAR classification criteria for IgG4-related disease in a large cohort from China
20
PubMed Central. Characterizing IgG4-related disease with 18F-FDG PET/CT: a prospective cohort study
21
Scientific Reports. Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study
22
PubMed Central. New Developments in the Treatment of IgG4-Related Disease: A Comprehensive Clinical Approach
23
Annals of the Rheumatic Diseases. Rituximab for IgG4-related disease: a prospective, open-label trial
24
PubMed. Long-term efficacy of maintenance therapy with Rituximab for IgG4-related disease
25
PubMed. Inebilizumab for Treatment of IgG4-Related Disease
26
PubMed Central. Increased cancer risk in patients with IgG4-related disease in a nationwide South Korean cohort, 2012–2021
27
Scientific Reports. Malignancy and IgG4-related disease: the incidence, related factors and prognosis from a prospective cohort study in China
28
The Journal of Rheumatology. Association Between Immunoglobulin G4–related Disease and Malignancy within 12 Years after Diagnosis: An Analysis after Longterm Followup